Clinical trial / 2005
Chondroitin sulfate treatment for 2 years significantly reduced joint space loss compared to placebo in patients with knee osteoarthritis.
In a randomized, double-blind, placebo-controlled trial, 300 patients with knee osteoarthritis were assigned to receive 800 mg chondroitin sulfate (CS) or placebo once daily for 2 years. Patients receiving placebo experienced a mean joint space loss of 0.14 +/- 0.61 mm after 2 years (P = 0.001 compared with baseline), whereas patients receiving CS showed no change (0.00 +/- 0.53 mm; P not significant compared with baseline). The difference in joint space loss between the two groups was significant for mean joint space width (0.14 +/- 0.57 mm; P = 0.04) and minimum joint space width (0.12 +/- 0.52 mm; P = 0.05). There was no significant symptomatic effect on pain or function, and CS was well tolerated.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 300 patients with knee osteoarthritis
- What was measured
- Joint space loss over 2 years, pain, and function
THE PAPER
Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial.
Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Arthritis Rheum, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.